Anti-VEGF therapy improves outcomes in retinal diseases by targeting neovascularization and macular edema, crucial in conditions like AMD and diabetic retinopathy. Optical coherence tomography is ...

Eye drop nanoparticles that shrink over time overcome the eye's natural defenses, delivering protein drugs to the retina and ...

Please provide your email address to receive an email when new articles are posted on . Continuous growth of macular neovascularization size, as well as development of outer retina atrophy, was ...

Researchers at Johns Hopkins University have identified a process in the eye that may explain why biologic drugs for treating age-related macular degeneration (AMD) fail in some patients. Using that ...

New research has found that the endothelial cell-specific A disintegrin and metalloproteinase domain-containing protein 10 (ADAM10) regulates abnormal blood vessel growth in the damaged retina, which ...

Manufacturing differences between ranibizumab and aflibercept biosimilars might shape pricing, uptake, and patient access globally.

Management of geographic atrophy (GA) has changed with the introduction of retinal therapies aimed at slowing disease ...

Please provide your email address to receive an email when new articles are posted on . Patients with inherited retinal diseases may present with seemingly routine conditions. Look for comorbid ...

Forbes contributors publish independent expert analyses and insights. This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to ...

Branch retinal vein occlusion (BRVO) is when a blockage forms in the veins branching off the retina, which can disrupt blood flow. Treatment depends on the type of blockage and severity of the damage.